Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cell, Journal Year: 2017, Volume and Issue: 168(4), P. 707 - 723

Published: Feb. 1, 2017

Language: Английский

---

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(3), P. 197 - 218

Published: Jan. 4, 2019

Language: Английский

---

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

Nature Immunology, Journal Year: 2016, Volume and Issue: 17(10), P. 1142 - 1149

Published: Sept. 20, 2016

Language: Английский

---

Cancer immunoediting and resistance to T cell-based immunotherapy

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 16(3), P. 151 - 167

Published: Dec. 6, 2018

Language: Английский

---

Immunotherapy in colorectal cancer: rationale, challenges and potential

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2019, Volume and Issue: 16(6), P. 361 - 375

Published: March 18, 2019

Language: Английский

---

Molecular mechanisms and cellular functions of cGAS–STING signalling

Nature Reviews Molecular Cell Biology, Journal Year: 2020, Volume and Issue: 21(9), P. 501 - 521

Published: May 18, 2020

Language: Английский

---

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Cancer Discovery, Journal Year: 2018, Volume and Issue: 8(7), P. 822 - 835

Published: May 17, 2018

Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine efficacy PD-1 inhibitors these subgroups. Objective response rates to blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) (P < 0.001) Stand Up To Cancer (SU2C) cohort (174 patients) with LUAC patients treated nivolumab CheckMate-057 phase III trial (0% vs. 57.1% 18.2%; P = 0.047). In SU2C cohort, exhibited shorter progression-free overall 0.0015) survival compared KRASMUT;STK11/LKB1WT Among 924 LUACs, alterations were only marker associated PD-L1 negativity TMBIntermediate/High The impact on clinical outcomes PD-1/PD-L1 extended PD-L1–positive non–small cell cancer. Kras-mutant murine models, Stk11/Lkb1 loss promoted inhibitor resistance, suggesting a causal role. Our results identify as major primary resistance Significance: This work identifies prevalent genomic axis adenocarcinoma. Genomic profiling may enhance predictive utility expression tumor mutation burden facilitate establishment personalized combination immunotherapy approaches for genomically defined subsets. Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. article highlighted Issue feature, 781

Language: Английский

---

STING: infection, inflammation and cancer

Nature reviews. Immunology, Journal Year: 2015, Volume and Issue: 15(12), P. 760 - 770

Published: Nov. 25, 2015

Language: Английский

---

DNA sensing by the cGAS–STING pathway in health and disease

Nature Reviews Genetics, Journal Year: 2019, Volume and Issue: 20(11), P. 657 - 674

Published: July 29, 2019

Language: Английский

---

Therapeutic cancer vaccines

Nature reviews. Cancer, Journal Year: 2021, Volume and Issue: 21(6), P. 360 - 378

Published: April 27, 2021

Language: Английский

---